Levetiracetam pharmacokinetics analysis and elucidation of appropriate administration design in critically ill patients

Levetiracetam pharmacokinetics analysis and elucidation of appropriate administration design in critically ill patients - Levetiracetam pharmacokinetics analysis and elucidation of appropriate administration design in critically ill patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000043164

Enrollment

Registered

2021-01-29

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severely ill patients requiring administration of antiepileptics drugs

Interventions

Immediately before the end of the infusion on the day when levetiracetam is administered, and 0.5,1,2,4,8and12 hours after the end of the infusion,a total of 7 blood samples and dialysis filtrate are

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Inpatients receiving levetiracetam in the ICU 2)Patients over 20 years old 3)Patients whose consent has been obtained in writing by the person or his / her substitute

Exclusion criteria

Exclusion criteria: 1) When an adverse event occurs 2)When the underlying disease worsens and the doctor in charge decides that it should be the center 3)A serious violation of the research implementation plan was found. 4)The subject canceled the research participation. 5)The subject's cooperation could not be obtained.

Design outcomes

Primary

Measure	Time frame
Comparison of Levetiracetam pharmacokinetics by renal function	—

Countries

Japan

Contacts

Public Contactmana taguchi

Hyogo College of Medicine Intensive Care Unit

bbbsc333mana@gmail.com0798-45-6389

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026